Apparently, I missed some yoga trends in my most recent post. There are others.
For example: beer yoga.
Beer Yoga is yoga…with, yes, beer. German yogis BierYoga are reportedly the major first innovators, offering classes and workshops after seeing it being taught at the Burning Man festival. Since January, the idea’s spread internationally. Here are two recent articles on beer yoga.
Health and fitness trends evolve. Technology and imperatives in business force change. Consumers in health want fresh ideas and products. From Tae Boe to Thighmasters. From Bowflex to Bodyblade and belt massagers. Yoga is no different.
Yoga is becoming increasingly popular in the United States. About 37 million Americans practiced yoga at the beginning of 2016 and more than 80 million Americans were likely to try yoga at some point in the year, according to a study in Yoga Journal.
With all these potential pupils, teachers innovate. They employ new techniques and tricks. They use props and blend practices. Here are some examples in 2017.
Mobile Yoga (as in phones and apps)
Live Music Yoga
Say what you will about these types of yoga, they’re coming your way. (That is, if they haven’t already!)
Yoga Retreats & Vacations
From the Guardian newspaper. “You can’t move for downward dog opportunities these days. The explosion of yoga in western countries means there’s a studio on every other street and such a variety of styles and options, that choosing a holiday or retreat can be overwhelming. So where to start? It makes sense to try a weekend away before committing to a whole week. One possibility is to choose a teacher you know or like the sound of and see if they’re running anything that suits. Or you could pick a venue you fancy and see what teachers are hosting holidays there. Think about what you want too – some combine yoga with other activities (maybe good for those with non-yogi partners), some are vegan, some don’t ban booze – it’s always worth asking before you book.”
Here, mobile yoga studio have modified so that the “studio” travels to where the people may be…at work, shopping, at play, in the community. Yoga apps brings teachers right to your home!
From the New York Times: “Soul Stretch Mobile Yoga is a novel concept to the Cleveland area,” explains Rose Sabin, co-owner of the company with her daughter-in-law, Natalie Sabin. The mobile studio concept has worked well in other cities, “like Los Angeles, New York, Chicago” according to Sabin, “but this is Cleveland’s first mobile yoga studio.” Sabin’s goal for the company is two-fold: first, to bring yoga to the people by making it accessible and secondly, to help promote local businesses by bringing the unique offering of yoga class to a community business. As an advertising agency owner, Sabin understands all aspects of running a small business like certifications, insurance and marketing. She would like to help other business owners by allowing them to offer her company’s services and “expose more people to the beautiful, healing therapy of yoga.”
“Yoga Therapy uses the tools that you would find in many Yoga classes; postures, working with the breath, meditation, awareness of the body and/or mind, relaxation, and these are directed to the needs and ability of the person concerned. The aim is to promote good health for the person as a whole – the emphasis of this work may be towards the body, the mind, the emotions or a combination of these. A health problem may be primarily in one of these aspects, for example, back pain caused by poor posture. Yoga Therapy would then focus on working with the body and Yoga postures. If the back pain is exacerbated by stress, then including Yoga to help calm the mind, for example breathing techniques, will be very useful too. Our health is a dynamic combination of body and mind. Long term physical conditions are commmonly associated with depression and a variety of feelings – sadness, loss, frustration, anger. Our emotional health affects our physical health too, although this is difficult to quantify. Yoga can bring us awareness of the body and mind; and more understanding of how to help the body, emotions or patterns of thinking and provides a practical approach to developing a positive state of health.”
For Georg Feuerstein in the Huffington Post, “Yoga therapy is of modern coinage and represents a first effort to integrate traditional yogic concepts and techniques with Western medical and psychological knowledge.”
According to the official website of AcroYoga, “it is a beautiful blend of ‘the wisdom of yoga, the dynamic power of acrobatics and the loving kindness of Thai massage’.” It was founded by Jenny Sauer-Klein and Jason Nemer in 2003. The 3 main aspects of this form of yoga are trust, playfulness and a sense of community. Acro Yoga constitutes 3 elements: the Solar Acrobatic Practice, the Lunar Healing Arts, and the Yogic Practices.
That makes a lot of sense. Have you seen a change in which styles of yoga have been more popular over the years? I can’t necessarily track it through the decades, but I would say that vinyasa is more of a recent trend. Historically I think it was more Iyengar, more of that traditional track. What I’m seeing rising in popularity now is definitely the more restorative classes, like Yin. Part of that is because people are recognizing the greater benefits. There’s been a lot of research on what restorative can do for you beyond just stress relief. I’m also seeing a rise in the popularity of Kundalini...I think it’s really interesting and not necessarily what I would have anticipated.
Maybe a reaction to the it’s-all-about-sweat set. How do you feel about the crazy amount of commercialization around yoga in the past few years? Is it good or bad for yoga? Honestly, we get overwhelmed by the number of new products out there, and it’s hard to determine what’s good and what’s worth your dollars. And what’s so awesome about yoga is you really don’t need much to do it. It’s “have mat, will practice” pretty much. All the other stuff can be great and fun but is maybe not necessary. We hear all different opinions—some people really want to know what the best new yoga pant is and then some don’t, they just want to stick to the practice and be more traditional about it. I think it probably does get more people on the mat, though, and that’s a good thing.
“Anyone who has ever gone for a run, jog or even a walk knows that uplifting, happy feeling they get at the end of their journey. Some call it the ‘runner’s high’, others put it down to endorphins, here William Pullen teaches us focus that incredible energy to experience our emotions in motion.
“In Run for Your Life, Pullen argues that we need a radical new approach to mindfulness – an approach which originates in the body itself. DRT offers just that.
“Whether the you are looking for strategies to cope with anxiety, anger, change, or decision-making, Run for Your Life offers carefully-tailored thought exercises (and talking therapies for pairs or groups) inspired by mindfulness and Cognitive Behavioural Therapy, specifically designed to be implemented whilst on a run or walk. The book is designed to offer space for you to reflect on your practice and see your progress as you run through life’s ups and downs.”
Pullen, a London-based psychotherapist, came up with Dynamic Running Therapy (DRT) and there’s an app to go along with the book.
It immediately made me think of the first (silly) article I wrote as a PhD student in London.
(Man, it’s funny to recognize that eleven years have elapsed since the publication of the article above!)
The idea then was that running might alleviate some of the PhD blues. But Pullen has taken it to a whole new (and more) comprehensive level. His book is definitely worth a read.
How will the pharmaceutical industry be impacted under the Trump administration? Who’s the new FDA Commissioner? How will e-cigarettes be effected? How will the opioid crisis be impacted?
Trump’s FDA and “the United States of Oxy”
By Lucas Richert
The US Food and Drug Administration (FDA) may be headed for a major overhaul under the Trump presidency and the agency’s new head, Scott Gottlieb. At a recent meeting with pharmaceutical industry leaders, President Trump asserted that “we’re going to be cutting regulations at a level that nobody’s ever seen before.” His most recent statements, made at a White House confab, echoed loudly throughout the medical and pharmaceutical industries.
Just talk? It’s tough to say, yet supporters of pharmaceutical deregulation have long wanted to reduce bureaucracy and lessen oversight of drugs and devices. Critics, by contrast, contend the drugs market could be destabilized and public health undermined. The tricky task will be to strike the proper balance of speed and safety, as well product innovation and consumer protections.
Scott Gottlieb, a physician and regulator recently approved to lead the agency by the US Senate in a 57-42 vote, pledged he would lower prices, reduce approval times, and fight the widespread abuse of opioid painkillers. This kind of addiction, said Gottlieb, was “a public health crisis of staggering human and economic proportion.”
This rhetoric and attempted reforms at FDA are not new, but the devastating painkiller crisis certainly is.
Gottlieb’s critics noted that he was too closely tied with the pharmaceutical industry to tackle the opioid epidemic. “We are suffering this public health epidemic because big pharma pushed pills they knew were dangerous and addictive, the FDA approved them, Senator Ed Markey (D-Mass) told reporters. The United States had been turned into the “United States of Oxy,” Markey added.
The FDA approved OxyContin, a powerful opioid to treat severe pain, such as in the case of patients with terminal cancer. With mild pain, though, the FDA deemed the dangers of addiction too great, and has not allowed the marketing of Oxy for such pain.
Not able to solve the opioid alone, the FDA nonetheless will play an important role. He has made this case quite forcefully. However, Gottlieb’s critics (mainly Democrats) have pointed to his past views on the regulation of opioids. In particular, he has suggested that policies restricting pharmacies and drug distributors might burden innocent patients.
This will be one of the defining issues of his career.
The Food and Drug Administration’s move in May, 2016 to crack down on e-cigarettes brought regulation in line with existing rules for cigarettes, smokeless tobacco and roll-your-own tobacco. This had been highly anticipated after the FDA issued a proposed rule over two years ago.
“Millions of kids are being introduced to nicotine every year, a new generation hooked on a highly addictive chemical,” U.S. Secretary of Health and Human Services Sylvia Burwell stated during the announcement of the new rules. She asserted, too, that health officials still didn’t have the scientific evidence showing e-cigarettes can help smokers quit, as the industry asserts, and avoid the known ills of tobacco.
The Trump administration recently approved a delay in the FDA’s e-cigs guidelines. It was a decision that divided officials in the public health establishment. And it’s undoubtedly true that several Trump administration officials, including FDA chief Gottlieb, have connections to the e-cig and tobacco industry.
From March 2015 to May 2016, according to Bloomberg, Gottlieb was a director of Kure Corp., a Charlotte, North Carolina-based firm that distributes e-juices and vaping pens in coffeehouse-style lounges known as vaporiums. Of course, he had a financial interest in the company as of March, according to financial and ethics disclosures, and promised to sell his stake if confirmed as head of the FDA.
“How to regulate e-cigarettes is one of the most critical questions on tobacco regulation that the FDA is going to be facing in the coming years,’’ said Vince Willmore, a spokesman for Washington-based Campaign for Tobacco-Free Kids.
Vaping will also be a significant issue for Gottlieb and the FDA. Getting the regulation right matters – not just in the U.S., but places like Glasgow and Vancouver.
The writer Matthew Herper suggested recently how “talk of speeding up [drug] approvals for serious diseases first gained traction in the early 2000s.” Actually, the trend extends much further back. Debate about quickening drug approvals has a complex and compelling history.
The FDA under President Ronald Reagan, for instance, offers a useful tool to evaluate the Trump administration’s approach to the FDA and the drug industry.
In mid-January, as Mr. Trump awaited his inauguration and the transition team worked furiously to establish his cabinet and select suitable agency nominees, the FDA generated serious debate. Trump met with Jim O’Neill, a venture capitalist, and a close friend of PayPal’s Peter Thiel. He met with Balaji Srinivasan, a cofounder of genetics testing firm Counsyl.
Both men subscribed to the idea – now conservative doctrine, according toForbes – that the FDA prevented a flood of new drugs from hitting the market. Neither held an M.D., which has been for years a prerequisite for the FDA’s top job. Yet, by 20 January the frontrunner for the Commissioner’s job was Gottlieb, who had made it known publicly he believed the FDA should trim bureaucratic red tape and approve drugs in a speedier fashion.
Trump ultimately settled on Gottlieb, whose selection was welcomed by the pharmaceuticals sector. His ties to industry were questioned by Democrats, but the vote wasn’t close.
The Gipper’s FDA
Ronald Reagan, whether as a candidate or later President of the United States, did not desire the dismantling of the FDA, but neither did he trust it. In his optimistic view, its authority, like that of many other regulatory agencies, simply needed curtailing.
In 1975, he told an audience at the American Enterprise Institute, a conservative think tank, that the FDA was hurting Americans, yet also made clear he did not wish to totally “eliminate the responsibility of the FDA…”
The problem, as Reagan saw it, rested in the restriction of freedom of choice for American consumers, since the agency had established itself “as the doctor and decided that they will tell us what medicines are effective.” He felt that a degree of regulation was necessary to protect Americans from each other, but the FDA had overreached and, as bureaucracies do, went beyond “protecting us from poisonous or harmful substances…”
In 1980, the Republican presidential ticket of Ronald Reagan and George Bush promised to change Washington. President Jimmy Carter represented failure, Republicans argued, be it botched rescue attempts and helicopter crashes in the desert, the loss of the Panama Canal, or an impotent economy. The jaunty and upbeat Reagan succeeded in shifting the policy discourse about the size and scope of federal government programs; harkening back to halcyon days, he moved the conversation about which government program to launch (or expand) to how much of a program’s or agency’s budget ought to be cut.
In 1981, the debate about drug regulation continued to polarize people; finding a middle ground was often difficult, and as the new administration took power, the outgoing FDA Commissioner Goyan articulated a consensus-oriented, centrist approach to drug regulation. Think tanks such as the Heritage Foundation and American Enterprise Institute promulgated changes to the FDA’s mission as a means of unleashing the once-mighty American pharmaceutical industry. This would fuel the U.S. industry and the greater economy.
For some, the FDA transcended presidential politics and ideology. It protected all Americans – conservative and liberal – as it carried out its duties. “My view,” said the bearded, grey, and somewhat feisty Jere Goyan, “is that government regulation needs to strike a balance between preserving the maximum freedom for individuals while at the same time establishing the rules that are needed for us to live together, to survive as a society.”
By voting for Reagan, Americans indicated they wanted “modifications” to the current models – reform rather than removal. “It would be a mistake,” Goyan argued, “a tragic one, to interpret the election results to mean that the public wants a lessening of the standards that provide the foundation for the food and drug industries in this country, standards that make our food and drug supply the best in the world.”
Often, his approach went unheeded, overwhelmed by disputes about individualism and consumer choice and bureaucratic incompetence. One the one hand, many Americans regarded FDA staff members “as a bunch of demented bureaucrats running amok,” even though the agency’s “balanced” regulation of drugs was both “socially valid and moral.”
On the other hand, the president of the Pharmaceutical Manufacturers Association illustrated an alternative. Lewis Engman felt that taking medicines, like smoking cigarettes, was a matter of personal choice. “Any time you interfere with the basic market system,” he said in 1981, “you’re in trouble…the consumer is his own best guardian.”
Impossible as it was to know how the new president would transform the FDA in early 1981, political pundits, economic analysts and pharmaceutical industry insiders suggested that Reagan meant less regulation, which meant industry growth. The President of the National Association of Retail Druggists (NARD), Jesse M. Pike, sent a congratulatory letter to Reagan. It emphasized how delighted NARD was to see him in the White House and just how his regulatory reform beliefs would be good for business. In Pharmaceutical Technology, James Dickinson wrote, “everyone expects life to be easier for industry under the new Reagan Administration.”
Apparently, the Washington cocktail circuit was rife with speculation about the new administration repealing the Kefauver-Harris 1962 drug efficacy requirements – a move that would further enhance prospects for industry growth. This was nonsense, according to knowledgeable policymakers and reporters. Still, the fact that the notion was even bandied about, however fancifully, represented a substantial change in the debate about drug regulation.
The press envisaged a pharmaceutical industry boom in the near future. Newspapers reported how “The Drug Business Sees a Golden Era Ahead” and that pharmaceutical associations were positively giddy. Rep. James Scheuer (D-NY) publicly denounced the agency’s over-cautiousness and emphasized the need for immediate reform. It was risk averse, to the detriment of sick Americans. Moxalactum, he argued, was an American-made antibiotic for pneumonia used by Marshal Tito in Yugoslavia – yet it was not available in the United States. The narrative Scheuer framed was that the FDA was protecting Americans to death – and this before the onset of the HIV/AIDS crisis.
Mounting enthusiasm about pharmaceutical growth in the wake of the Reagan election was palpable. Reports indicated that the pharmaceutical industry and investors were confident about the future – a golden era – in this new regulatory climate. There was bullishness about drug stocks in general, and many predictions that pharmaceutical companies would start to generate more and more earning in 1981 and 1982. Overall, these stories proved to be accurate.
Ronald Reagan, however, had pledged in 1980, with trademark sincerity, not to gut the FDA. Rather, he made oblique references to the agency’s storied history and resorted to prosaic comments about the danger of hidebound power-hungry bureaucracies. “There’s a certain amount of regulation that is always necessary to protect us from each other,” he told CBS’s Walter Cronkite. “And that I recognize. We don’t want to, for example, eliminate the responsibility of the FDA…”
Much can be gleaned from Reagan’s public statements about the Food and Drug Administration, but they fail to reveal the entire picture. On May 20, 1986, Reagan described a meeting between Paul Laxalt, Jack Dreyfus, and himself. Dreyfus, who had “spent $50 mil. of his own money” was attempting to have the epilepsy drug Dilantin approved and found a roadblock in the form of the FDA. According to Reagan’s personal diary: “The villain in the case is the Fed. Drug Admin & they are a villain.”
Red Herrings and Empowered Patients
Under the Trump administration, will the FDA play the villain role? President Trump will build on earlier Republican efforts to streamline the agency, whether these took place during Reagan or Bush presidencies. He has promised to remove barriers for overseas drugs and support ‘Right to Try’ laws, which will attempt to provide access to unapproved drugs. Indeed, some of these measures may help patients. And the Trump administration will be the right track if it can safely accelerate drug approvals, promote production and use of generics, and lower drug prices through increased competition.
Gottlieb and others have suggested they would radically restructure the drug approval process – even if that remains something of a red herring argument. QuintilesIMS Institute, among various other organizations, have determined that the total time between patent and approval has dropped 31% since 2008. Yale researchers hold that the FDA is already considerably faster than Europe and Canada when it comes to approving drugs.
Another area of regulation that ought to be monitored closely is advertising. Every other nation besides the US and New Zealand has concluded that advertising powerful drugs for treating complex illnesses makes no sense when your target market lacks the qualifications to fully grasp the risks. How will powerful painkillers be regulated in the years ahead.
The drug industry wants to empower patients, to invest them in the writing of prescriptions. Looking ahead, it will be important to watch the administration’s and FDA’s role in faciliating this.
“The [industry] idea is that consumers are central players in their health management and therefore have a right to be informed of different drugs,” Lewis Grossman, a specialist in food and drug law, told the Los Angeles Times.
Yet, the practice of medicine should not be placed in the hands of amateurs and junk scientists. In the post-truth era, however, when an opioid epidemic soars and drug prices are hitting Americans in the pocketbooks, these “facts” could be lost in the noise.
Thanks for reading. For more, please follow the blog.
Lucas Richert is a Lecturer in History at the University of Strathclyde (Glasgow, UK). He is the author of Conservatism, Consumer Choice, and the Food and Drug Administration during the Reagan Era. He’s currently at work on a second book, tentatively called Strange Medicines: Drugs, Science, and Big Pharma in Culture.
Since the re-emergence of science in Europe in the High Middle Ages down to the present the relationship between science and religion has been a very complex and multifaceted one that cannot be reduced to a simple formula or a handful of clichés. Many of the practitioners, who produced that science, were themselves active servants of their respective churches and many of their colleagues, whilst not clerics, were devoted believers and deeply religious. On they other had there were those within the various church communities, who were deeply suspicious of or even openly hostile to the newly won scientific knowledge that they saw as a threat to their beliefs. Over the centuries positions changed constantly and oft radically and any historian, who wishes to investigate and understand that relationship at any particular time or in any given period needs to tread very carefully and above all not to approach their…
I’m delighted that professional photographer Morgan Scott shares his images and ideas. Most of the time he works in London as a Business Development Manager for Bijou Commerce. But photography, as he puts it, has been a long-standing ‘passion.’
In a multicultural city such as London, you will, for sure, encounter a plethora of amazing faces, fashions, cultures and personalities. It’s a candy shop of choice when it comes to portrait photography opportunities. It’s a great place to immortalize elements of the body.
There are two main types of street portrait photography styles. The first is when your subject is unaware of their photo being taken (at first at least) and the photographer is using a hide-and-seek approach. A good example is Vivian Maier, who used a Rolleiflex film camera in the 50s and 60s and which you would shoot from the navel. The subjects were unaware of the camera as it was not held up at eye level. Vivian’s photos gave the subject a very grand feeling as the portrait was taken at an angle looking up at them, even if the subject themselves were not a grand figure in stature or being.
Maier only became famous post mortem, when a lot of film was purchased at auction by John Maloof. Maloof discovered that Maier was arguably one of the most significant street photographers of the twentieth centary and made the fantastic documentary ‘Finding Vivian Maier’, as well as curating her work. Finding Maier’s undeveloped films, hundreds of them, was the photography equivalent of discovering buried treasure.
She did also take portraits where the subject was fully aware a photo was being taken, although many were very natural, unforced forced poses. Perhaps she was lightning quick and somewhat unthreatening as a woman with a camera or perhaps it was simply not the norm to be photographed like in our camera-phone, Instagram world today.
This takes us to the second type of street portrait: the ‘aware’ subject. This is a style I quite enjoy myself. The way I go about this is to wander/wonder about the streets looking for people with interesting styles and faces. I generally go by gut feeling – instinct, I suppose – about whether I want to take a portrait of someone or not. It’s usually based on a fleeting glance. So the first challenge is to find a subject, which is not too hard to do in London. The second challenge is approaching that person and asking permission to take their portrait. It’s all to do with the approach and manner you adopt. Because I seek out slightly ‘alternative’ looking people to take portraits of, they are generally more likely to say yes as there is an element of how they look that they want to be noticed in most cases. Why have purple hair if no one sees it, right?
When I approach the person I do it calmly, with a genuine smile, and say: “Excuse me, I’m doing a personal photography project on London Style (I point to my camera around my neck) and I love your look. If you don’t mind I would love to take your portrait. I’ll give you my website and you can save the photo and use it however you want for free.” The majority of the time a subject will say yes because s/he are flattered. If someone says no, I figure out if it’s just a shy no; some people are a little embarrassed at first and I’ll say ‘Oh go on you look great’, and they will. You can just tell when someone really is not interested and in this case I don’t push it and say ‘Ok no worries, cheers.’ Remember there’s always another opportunity right up the street. I also don’t want to look at a photo with a reluctant pose as it’s a little bit negative – meaning I won’t have the portrait I desire.
I was inspired by the ‘Humans of New York’ series by Brandon Stanton. His photos feature an eclectic bunch of people, and the portraits are aimed at revealing relatable, human stories. These portraits highlight human whole, from head to toe, displaying the subject in all his/her glory and interesting fashions. These are also posed portraits, considering they are also telling their story to Stanton and have been made into a series of books.
For me, taking portraits is a passion. Faces tell a story and the eyes really are a window to the soul. It’s exciting for me to stop strangers, take their portrait and make a friend. Art is literally walking by us everyday, the art of the human, the art of human expression. What we see in the cities of the world is really an expression of the zeitgeist – a particular mindset, politics, and art – and it will never happen again; photography can freeze the essence of present time for future generations to enjoy and say “Look what they used to wear!”
Sexual harassment, misconduct and gender violence by university staff are at epidemic levels in the UK, a Guardian investigation suggests. The body is being abused in higher education, and we need to think about this much more closely and much more critically.
According to David Batty, Sally Weale and Caroline Bannock, freedom of information (FoI) requests sent to 120 universities found that students made at least 169 such allegations against academic and non-academic staff from 2011-12 to 2016-17. At least another 127 allegations about staff were made by colleagues.
But scores of alleged victims have told the Guardian they were dissuaded from making official complaints, and either withdrew their allegations or settled for an informal resolution. Many others said they never reported their harassment, fearful of the impact on their education or careers. This suggests that the true scale of the problem is far greater than the FoI figures reveal.
It’s my pleasure to promote the publication of an important Policy Brief on Cannabis by Kathleen Thompson. Over the past few years she has helped drive conversations about the consumption and control of marijuana. Her recent Policy Brief ought to be read by anyone and everyone! Here’s an extract.
LEGALIZATION OF CANNABIS: THE POLICY CHALLENGES AND OPPORTUNITIES
By Kathleen Thompson, PhD, MSW, RSW, BA (Hons)
“The commitment by the Government of Canada to legalize cannabis
and cannabis products presents a complex range of socio-economic
challenges and opportunities. Creating the right legal and regulatory
framework to address the implications, both good and bad, will be
key in determining whether legalization is deemed successful public
The federal government plans to introduce cannabis legislation in the
coming spring session of Parliament. The legislation will be based on
the recommendations contained in a report issued on November 30 by
a Task Force of experts who studied the issue for the past year. The Task
Force received input from more than 30,000 Canadians, organizations
and professionals. Entitled “A Framework for the Legalization and
Regulation of Cannabis in Canada”, the report recommends allowing
more flexibility in the current federally controlled cannabis cultivation
model. Specifically, the federal government would regulate a safe and
responsible supply chain of cannabis.”
Dr. Thompson has worked in health policy analysis and research as a bureaucrat and as a consultant for the last 25 years, specializing in the mental health, disability and corrections sectors.
In 2015, Dr. Thompson created the Cannabis Regulatory Research Group. The focus of the policy research group is on promoting collaborative public policy processes and evidenced-based research with the cannabis industry, governments, academia, civil society and at the United Nations. Additionally, Dr. Thompson consults with individuals and organizations on how to enter the legal cannabis industry.
Richard Roope, of the RCGP, has recently released a report on e-cigarettes.
Essentially, the Royal College of General Practitioners, the official channel for General Practice of Medicine in the UK, has given their informed recommendations to health professionals regarding smoking cessation and the use of e-cigarette.
1. GPs provide advice on the relative risks of smoking and e-cigarette use, and provide effective referral routes into stop smoking services.
2. GPs engage actively with smokers who want to quit with the help of e-cigarettes.
3. Where a patient wants to quit smoking, and has not succeeded with other options, GPs should recommend and support the use of ENDS.
[GENEVA – Electronic nicotine delivery systems (ENDS), of which electronic cigarettes are the most common prototype, are devices that do not burn or use tobacco leaves but instead vaporise a solution the user then inhales. The main constituents of the solution, in addition to nicotine when nicotine is present, are propylene glycol, with or without glycerol and flavouring agents. ENDS solutions and emissions contain other chemicals, some of them considered to be toxicants.The World Health Organization (WHO) submitted a report on Electronic nicotine delivery systems to the sixth session of Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP 6), which occured in Moscow, Russian Federation, from 13 to 18 October 2014.]
4. GPs recognise ENDS offer a wide reaching, low-cost intervention to reduce smoking (especially deprived groups in society and those with poor mental health, both having elevated rates of smoking).
5. All GPs encourage smokers who want to use e-cigarettes as an aid to quit smoking to seek the support of local stop smoking services.
Harm-reduction has come out on top. Vape Fear has lost this one.
I have written my fair share about e-cigarettes in Canada, the United States, and Great Britain.
* ‘Why Aren’t we Regulating E-Cigarettes?,’ Regina Leader-Post [May 16, 2016]
* ‘Let’s Get Proactive with E-cigarettes,’ Saskatoon Star Phoenix [April 24, 2015].
* ‘Lot of Smoke and Mirrors with Vape Policy,’ Saskatoon Star Phoenix [November 28, 2014]
Often, I have suggested a measured response. My sense is, a little bit of regulation can go a long way. Minor rules can make a major difference. Don’t go overboard, but the waters are rough. Vaping should play by the rules, basically.
With my last op-ed back in May, people in Canada weren’t impressed with my approach. Folks were not interested in a middle-ground perspective. Here’s a list of the harshest responses to my articles on vaping. I’m basically the Red Skull mixed with Lex Luthor for suggesting some thoughtful rules might be in order.
1. “Please take the check that you earned from writing this trash and take an ethics course. Or a journalism degree.”
(Uh, I didn’t get paid. Woulda been nice.)
2. “It’s pretty obvious you don’t quite understand how the system works here in Canada…”
(Does anybody. There are no regulations? Ha.)
3. “You help tobacco companies profit from murder.”
(Jeez, really?! C’mon it’s my birthday.)
4. “…governments are making decisions based on MONEY, NOT PUBLIC HEALTH.”
5. “What tobacco lobbyist wrote this trash?”
(I’m no tobacco lobbyist, but I sure do think they’re funny in the movies. Aaron Eckhart, anyone?)